Abstract
The aim of this study was to compare the clinical characteristics of uric acid stones and their potential risk for chronic kidney disease (CKD). A total of 401 patients (196 with uric acid stone and 205 without) were enrolled from our database of patients with urolithiasis. We analyzed the clinical demographic features, stone location, urine chemistries, and renal function. There was a significant difference (p < 0.001) between the two groups in terms of age, with the higher mean age in the uric acid group. Patients with uric acid stones had much lower pH of urine (p < 0.001) and higher serum uric acid level (p = 0.002). Notably, those with uric acid stones had worse eGFR than those with non-uric acid stones. Multivariate analysis confirmed that age over 60 years (ORs = 9.19; 95% CI 3.5–24.3), female sex (ORs = 4.01; 95% CI 1.8-9.0), hyperuricemia (ORs = 8.47; 95% CI 1.6–43.5), and uric acid stone (OR = 2.86; 95% CI 1.2–6.7) were the independent predictors of poor prognoses in CKD. Therefore, an association exists between uric acid stones and higher prevalence of CKD. Patients with uric acid stones may need close monitoring of renal function during follow-up.
Similar content being viewed by others
References
Curhan GC (2007) Epidemiology of stone disease. Urol Clin N Am 34:287e93
Sakhaee K (2008) Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens 17:304–309
Sakhaee K (2014) Epidemiology and clinical pathophysiology of uric acid kidney stones. J Nephrol 27:241–245
Trinchieri A, Montanari E (2017) Prevalence of renal uric acid stones in the adult. Urolithiasis. https://doi.org/10.1007/s00240-017-0962-5
Daudon M, Traxer O, Conort P, Lacour B, Jungers P (2006) Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 17:2026–2033
Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K (2007) Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol 2:883–888
Gambaro G, Croppi E, Bushinsky D, Jaeger P, Cupisti A, Ticinesi A, Mazzaferro S, D’Addessi A, Ferraro PM (2017) The risk of chronic kidney disease associated with urolithiasis and its urological treatments: a review. J Urol 198:268–273
Haley WE, Enders FT, Vaughan LE, Mehta RA, Thoman ME, Vrtiska TJ, Krambeck AE, Lieske JC, Rule AD (2016) Kidney function after the first kidney stone event. Mayo Clin Proc 91:1744–1752
Rule AD, Krambeck AE, Lieske JC (2011) Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol 6:2069–2075
Chou YH, Li CC, Hsu H, Chang WC, Liu CC, Li WM, Ke HL, Lee MH, Liu ME, Pan SC, Wang HS (2011) Renal function in patients with urinary stones of varying compositions. Kaohsiung J Med Sci 27:264–267
Worcester EM1, Parks JH, Evan AP (2006) Renal function in patients with nephrolithiasis. J Urol 176:600–603
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612
Denburg MR, Jemielita TO, Tasian GE, Haynes K, Mucksavage P, Shults J, Copelovitch L (2015) Assessing the risk of incident hypertension and chronic kidney disease after exposure to shockwave lithotripsy and ureteroscopy. Kidney Int 89:185–192
Coe FL, Evan AP, Worcester EM, Lingeman JE (2010) Three pathways for human kidney stone formation. Urol Res 38:147–160
Worcester E, Parks JH, Josephson MA, Thisted RA, Coe FL (2003) Causes and consequences of kidney loss in patients with nephrolithiasis. Kidney Int 64:2204–2213
Gaudio KM, Siegel NJ, Hayslett JP, Kashgarian M (1980) Renal perfusion and intratubular pressure during ureteral occlusion in the rat. Am J Physiol 238:F205–F209
Klahr S (2001) Urinary tract obstruction. Semin Nephrol 21:133–145
Klahr S, Morrissey J (2003) Obstructive nephropathy and renal fibrosis: the role of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int Suppl 87:105–112
Kadlec AO, Greco KA, Fridirici ZC, Gerber D, Turk TM (2011) Effect of renal function on urinary mineral excretion and stone composition. Urology 78:744–747
Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD (2011) Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 6:2364–2373
Viazzi F, Garneri D, Leoncini G, Gonnella A, Muiesan ML, Ambrosioni E et al (2014) Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study. Nutr Metab Cardiovasc Dis 24:921–927
Pinto-Sietsma SJ, Navis G, Janssen WM, de Zeeuw D, Gans RO, de Jong PE (2003) A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 41:733–741
Bagby SP (2004) Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease? J Am Soc Nephrol 15:2775–2791
Schelling JR, Sedor JR (2004) The metabolic syndrome as a risk factor for chronic kidney disease: more than a fat chance? J Am Soc Nephrol 15:2773–2774
Viazzi F, Piscitelli P, Giorda C, Ceriello A, Genovese S, Russo G, Guida P, Fioretto P, De Cosmo S, Pontremoli R, AMD-Annals Study Group (2017) Metabolic syndrome, serum uric acid and renal risk in patients with T2D. PLoS One 12:e0176058
Chou YC, Kuan JC, Yang T, Chou WY, Hsieh PC, Bai CH, You SL, Chen CH, Wei CY, Sun CA (2015) Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements. J Nephrol 28:457–462
Sairam K, Scoffone CM, Alken P, Turna B, Sodha HS, Rioja J, Wolf JS Jr, de la Rosette JJ, CROES PCNL Study Group (2012) Percutaneous nephrolithotomy and chronic kidney disease: results from the CROES PCNL Global Study. J Urol 188:1195–1200
Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, Buchholz N, Bushinsky D, Curhan GC, Ferraro PM, Fuster D, Goldfarb DS, Heilberg IP, Hess B, Lieske J, Marangella M, Milliner D, Preminger GM, Reis Santos JM, Sakhaee K, Sarica K, Siener R, Strazzullo P, Williams JC; Consensus Conference Group (2016) Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 29: 715–734
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
We declare no conflict of interest.
Ethical approval
All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
For this type of study, formal consent is not required.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Li, CC., Chien, TM., Wu, WJ. et al. Uric acid stones increase the risk of chronic kidney disease. Urolithiasis 46, 543–547 (2018). https://doi.org/10.1007/s00240-018-1050-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00240-018-1050-1